Popovits Kimberly J 4

4 · Kiniksa Pharmaceuticals International, plc · Filed Jun 2, 2026

AI-generated summary of this filing

Updated Jun 2, 2026

Kiniksa (KNSA) Director Kimberly Popovits Receives RSUs, Exercises Options

What Happened

Kimberly J. Popovits, a director of Kiniksa Pharmaceuticals International (KNSA), was granted and vested restricted share units (RSUs) and executed option/derivative activity on May 29, 2026.
She was awarded/vested a total of 14,184 RSUs (12,158 + 2,026) reported as derivative awards at $0.00 per unit, and there was an exercise/conversion of 2,799 option/derivative shares. The filing also shows a simultaneous disposition of 2,799 derivative shares. No market prices or cash values were reported in the filing for these transactions.

Key Details

Transaction dates: May 29, 2026 (filed on June 2, 2026). Filing appears timely (within the standard 2 business-day Form 4 window).
Transaction codes: A = Award/Grant (RSUs); M = Exercise or conversion of derivative securities.
Prices reported: RSUs shown at $0.00 per unit (derivative awards); one exercise entry shows price N/A and the disposition shows $0.00 — no cash value or open-market sale proceeds are reported.
Shares owned after the reported transactions: not specified in the excerpt provided.
Relevant footnotes:
- F1: Each RSU equals a contingent right to one Class A ordinary share.
- F3/F4: The RSUs vested in their entirety on May 29, 2026 (single installment; no expiration).
- F2: The related option vests in monthly installments starting from the May 29, 2026 grant date (final installment by the earlier of the one-year anniversary or the next annual meeting).

Context

These were derivative transactions (awards and an exercise/conversion), not open-market purchases. The filing does not state the purpose of the immediate disposition of the 2,799 shares (e.g., tax withholding or sale), so no conclusion about sentiment should be drawn.
Awards (RSUs vesting) are non-cash compensation and reflect grant/vesting events rather than purchases; purchases are typically viewed as more direct bullish signals for retail investors.

Form 4

Period: 2026-05-29

Director

Transactions

Exercise/Conversion
Class A Ordinary Share
[F1]
2026-05-29+2,799→ 15,345 total
Award
Share Option
[F2]
2026-05-29+12,158→ 12,158 total
Exercise: $48.38Exp: 2036-05-28→ Class A Ordinary Shares (12,158 underlying)
Award
Restricted Share Units
[F1][F3]
2026-05-29+2,026→ 2,026 total
→ Class A Ordinary Shares (2,026 underlying)
Exercise/Conversion
Restricted Share Units
[F1][F4]
2026-05-29−2,799→ 0 total
→ Class A Ordinary Shares (2,799 underlying)

Footnotes (4)

[F1]Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
[F2]The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant with the final installment vesting on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
[F3]The RSUs vest in their entirety on the earlier of a) the anniversary of the date of the grant and b) the date of the Issuer's annual meeting of shareholders in the following year. The date of the grant is May 29, 2026.
[F4]The RSUs vested in a single installment on May 29, 2026; there was no expiration date for the RSUs.

Signature

/s/ Douglas Barry, Attorney-in-Fact|2026-06-02

2 files